Head-to-head · free

Hims & Hers Health vs Cyclerion Therapeutics

HIMS vs KRSA — return on capital, cash generation, margins and balance sheet side by side.

HIMS

3 / 4

measures where HIMS leads

KRSA

1 / 4

measures where KRSA leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureHIMS · FY2025KRSA · FY2025
Revenue$2.3B$2.1M
Net income$128.4M(3.5M)
Revenue growth (yearly, multi-year)71.4%-19.3%
Free cash flow——
Free cash flow margin——
Net cash / (debt)——
ROIC——
Return on equity25.2%—
Gross margin73.8%—
Operating margin4.5%—
Net debt / EBITDA4.65x4.13x

Figures are as reported by each company; latest fiscal year shown.

Where Hims & Hers Health's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full HIMS profile →

Where Cyclerion Therapeutics's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full KRSA profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons